Small pancreatic ductal adenocarcinoma: our experience with emphasis on clinical and oncological outcomes

Objectives Pancreatic ductal adenocarcinoma (PDAC) is frequently unresectable and the prognosis is very poor despite recent advances. More than 50% of cases presents systemic disease while only around 6% of patients shows early PDAC. Even in the contest of early stage disease (Stage IA), complete resection may improve partially the long-term survival and only about 40% of treated patients survives 5 years or longer.

Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Federico Selvaggi, Manuela Bellobono, Antonio Umbriano, Severino Cericola, Vincenzo Casolino, Erica De Nicola, Fabio Marchionni, Eleonora Angelini, Simone Di Russo, Cinzia Baccaro, Roberto Cotellese, Lorenzo Mazzola Tags: 8. Pancreatic Cancer I Source Type: research